News

December 10, 2014, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014.  Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards (“IFRS”).

Management also announced that it has wound down its Phase 2 diabetic macular edema (“DME”) activities related to iCo-007.  iCo will continue to investigate  other potential use indications for its licensed technology, which targets the C-Raf kinase pathway.

“The Phase 2 iCo-007 DME data that has been presented,  along with our internal analysis,  has not demonstrated any subgroup response rates that warrant further financial investment by iCo in the DME program at this time,” said Andrew Rae, President & CEO of iCo Therapeutics.  “Since day one at iCo, we have been focused on redefining existing drug candidates for new or expanded use indications. We continue with that same model as we prepare for an oral Amphotericin B (“Oral AmpB”) clinical study, while concurrently investigating the ability to expand our proprietary oral delivery platform and  assessing complimentary assets which the Company may consider in-licensing or acquiring.”

(more…)

Taipei, Taiwan: December 9, 2014: Success Holding Group International Inc. (SHGT OTC: QB) (hereinafter referred to as “SHGT”) announces gross revenue earned of approximately USD $4,735,000 during November 2014. SHGT realized revenues of approximately $4,315,000 in November 2014 from weekly training seminars and $420,000 from advertising sponsorship of SHGT’s investment in the Internet movie.  Management believes SHGT is transitioning to full operating status and has become a multi-operating income and profitable company. Chairman, Steve Andrew Chen, states:  “SHGT has accumulated revenue of $12,250,000 and estimates by end of 2014, SHGT will reach $20,000,000 in revenue and pre-tax per share of approximately $0.50~$0.60 per share and fully expects future earnings to continue increasing.” (more…)

NEW YORK, NY – (December 2nd, 2014) – Glorywin Entertainment Group, Inc. (OTC: GWIN), a Nevada corporation, is pleased to announce the Financial Industry Regulatory Authority (FINRA) has approved the…

Charms Investments Ltd., a boutique management and advisory firm; with offices in Florida, New York and London has just launched their new corporate website along with a record setting year,…